Krilogy Financial’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Krilogy Financial’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-100	Closed	-$4K	–	718
2018 Q3	$4K	Buy	+100	New	+$2.85K	﹤0.01%	660
2018 Q2	–	Sell	-1,850	Closed	-$28K	–	659
2018 Q1	$28K	Buy	+1,850	New	+$44K	0.01%	403

Other funds holding MRNS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Krilogy Financial's MRNS Position: Q4 2018 in Review

Krilogy Financial sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2018, closing a stake of 100 shares — an estimated $4K sold.

Krilogy Financial first reported a position in MRNS in Q1 2018 and held it in 2 quarters. The position peaked at $28K in Q1 2018. 90 funds tracked by Wall St. Rank hold MRNS as of Q4 2018.

Krilogy Financial reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2018 after selling out during the quarter.
Krilogy Financial sold 100 Marinus Pharmaceuticals, Inc shares in Q4 2018, an estimated $4K.
Krilogy Financial first reported a position in Marinus Pharmaceuticals, Inc in Q1 2018 and held it in 2 quarters.
Krilogy Financial's Marinus Pharmaceuticals, Inc position peaked at $28K in Q1 2018.
90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2018.

Based on Krilogy Financial's 13F filing for Q4 2018, filed 14 Feb 2019.